Aminoglutethimide: Difference between revisions
m (Protected "Aminoglutethimide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 20: | Line 20: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Aminoglutethimide''' blocks the conversion of cholesterol to pregnenolone by inhibiting the enzyme desmolase, thus inhibits synthesis of all hormonally active steroids. It can be used in conjunction with other drugs for treatment of steroid-producing adrenocortical cancer. | '''Aminoglutethimide''' blocks the conversion of cholesterol to pregnenolone by inhibiting the enzyme desmolase, thus inhibits synthesis of all hormonally active steroids. It can be used in conjunction with other drugs for treatment of steroid-producing adrenocortical cancer. | ||
| Line 37: | Line 37: | ||
{{Sex hormones}} | {{Sex hormones}} | ||
[[Category:Aromatase inhibitors]] | [[Category:Aromatase inhibitors]] | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 22:04, 8 August 2012
 | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | Oral |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | >95% |
| Metabolism | Hepatic |
| Elimination half-life | 12.5 ± 1.6 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C13H16N2O2 |
| Molar mass | 232.278 g/mol |
|
WikiDoc Resources for Aminoglutethimide |
|
Articles |
|---|
|
Most recent articles on Aminoglutethimide Most cited articles on Aminoglutethimide |
|
Media |
|
Powerpoint slides on Aminoglutethimide |
|
Evidence Based Medicine |
|
Cochrane Collaboration on Aminoglutethimide |
|
Clinical Trials |
|
Ongoing Trials on Aminoglutethimide at Clinical Trials.gov Trial results on Aminoglutethimide Clinical Trials on Aminoglutethimide at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Aminoglutethimide NICE Guidance on Aminoglutethimide
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Aminoglutethimide Discussion groups on Aminoglutethimide Patient Handouts on Aminoglutethimide Directions to Hospitals Treating Aminoglutethimide Risk calculators and risk factors for Aminoglutethimide
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Aminoglutethimide |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Aminoglutethimide blocks the conversion of cholesterol to pregnenolone by inhibiting the enzyme desmolase, thus inhibits synthesis of all hormonally active steroids. It can be used in conjunction with other drugs for treatment of steroid-producing adrenocortical cancer.
Its major side effects are liver toxicity, inhibition of cortisol in the human body, and it may also cause hypothyroidism. Since cortisol helps break down muscle, aminoglutethimide is used by bodybuilders in a steroid cycle.
It is still used to suppress corticosteroid production in Cushing's Syndrome.
See also
External links
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Aromatase inhibitors
- Endocrinology